| Disease | IN THIS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, AFTER 4 WEEKS OF DIETARY STABILIZATION, 62 PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA WERERANDOMLY ASSIGNED IN A 1:1:1 RATIO TO RECEIVE 2 PLACEBO TABLETS, 2 POLICOSANOL 10-MG TABLETS
PLUS 1 MATCHED PLACEBO TABLET. PHYSICAL EXAMINATIONS WERE PERFORMED AND LIPID PROFILES AND BLOOD SAMPLES WERE OBTAINED AT BASELINE AND AFTER 4 AND 8 WEEKS OF THERAPY. THE INCIDENCE OF ADVERSE EVENTS (AES) AND COMPLIANCE WITH STUDY MEDICATIONS
WERE ALSO EVALUATED AT WEEK 4 AND WEEK 8 OF TREATMENT. THE 2 POLICOSANOL 20 MG/D REGIMENS WERE SIMILARLY EFFECTIVE. POLICOSANOL ADMINISTERED AS TWO 10-MG TABLETS SIGNIFICANTLY REDUCED TOTAL CHOLESTEROL (TC) (16.0%, P<0.001 VS BASELINE), LOW-
DENSITY LIPOPROTEIN CHOLESTEROL (LSL-C) (35.9%, P<0.001), AS WELL AS THE TC HIGH-DENSITY LIPOPROTEINCHOLESTEROL (HDL-C) RATIO (37.3%, P<0.001) AND LDL-C:HDL-C RATIO (52.4% P<0.001). THE REGIMEN SIGNIFICANTLY INCREASES HDL-C LEVELS (38.0%,
P<0.001 VS BASELINE). THE 20 MG POLICOSANOL TABLETALSO SIGNIFICANTLY DECREASED TC (20.0%). LDL-C. THESE RESULTS DEMONSTRATE THAT POLICOSANOL 20 MG/D IS AN EFFECTIVE AND WELL-TOLERATED CHOLESTEROL-LOWERING REGIMEN WHETHER ADMINISTERED AS A 20-MG
TABLET ONCE DAILY OR TWO 10-MG TABLETS ONCE DAILY WITH THE EVENING MEAL. |